Safety Evaluation of Contezolid (MRX-I) Versus Linezolid in Sprague-Dawley Rats
Abstract Background & Objectives Contezolid (MRX-I) is a novel ortho-fluorophenyl dihydropyridone developed by MicuRx Pharmaceuticals, Inc. It has been approved for the treatment of drug-resistant Gram-positive bacterial infections with relatively lower toxicity than other oxazolidinones such as...
Saved in:
| Main Authors: | Liping Wei, Min Hong, Min Lu, Yimin Qian, Qingmei Li, Naping Tang, Hua Li, Yan Chang, Yunliang Qiu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-05-01
|
| Series: | Drugs in R&D |
| Online Access: | https://doi.org/10.1007/s40268-025-00504-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Tolerability of Contezolid Versus Linezolid for Short-Term Treatment of Rifampicin-Resistant Pulmonary Tuberculosis: A Randomized Controlled Study
by: Wang J, et al.
Published: (2025-07-01) -
Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats
by: Seth Kwabena Amponsah, et al.
Published: (2019-03-01) -
Safety Assessment of Zigbir®: A Polyherbal Formulation in Sprague-Dawley Rats
by: Joseph Joshua Allan, et al.
Published: (2012-01-01) -
Subchronic and Chronic Toxicity Assessment of Sublancin in Sprague–Dawley Rats
by: Yong Guo, et al.
Published: (2025-05-01) -
Effect of fermented oyster extract on growth promotion in Sprague–Dawley rats
by: Hyesook Lee, et al.
Published: (2020-12-01)